Mass-spectrometry-based lipidomics

Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy

Background: Diabetic cardiomyopathy (DCM) is considered to be a distinct clinical entity independent of concomitant macro- and microvascular disorders, which is initiated partly by disturbances in energy substrates. This study was to observe the dynamic modulations of berberine in DCM rats and explore the changes of lipidomic profiles of myocardial tissue. Methods: Sprague-Dawley (SD) rats were fed high-sucrose and high-fat diet (HSHFD) for totally 22 weeks and intraperitoneally (i.p.) injected with 30 mg/kg of streptozotocin (STZ) at the fifth week to induce DCM. Seventy-two hours after STZ injection, the rats were orally given with berberine at 10, 30 mg/kg and metformin at 200 mg/kg, respectively. Dynamic changes of cardiac function, heart mass ratios and blood lipids were observed at f 4, 10, 16, and 22, respectively. Furthermore, lipid metabolites in myocardial tissue at week 16 were profiled by the ultra-high-performance liquid chromatography coupled to a quadruple time of flight mass spectrometer (UPLC/Q-TOF/MS) approach. Results: Berberine could protect against cardiac diastolic and systolic dysfunctions, as well as cardiac hypertrophy, and the most effective duration is with 16-week of administration. Meanwhile, 17 potential biomarkers of phosphatidylcholines (PCs), phosphatidylethanolamines (PEs) and sphingolipids (SMs) of DCM induced by HSFD/STZ were identified. The perturbations of lipidomic profiles could be partly reversed with berberine intervention, i.e., PC (16:0/20:4), PC (18:2/0:0), PC (18:0/18:2), PC (18:0/22:5), PC (20:4/0:0), PC (20:4/18:0), PC (20:4/18:1), PC (20:4/20:2), PE (18:2/0:0), and SM (d18:0/16:0). Conclusions: These results indicated a close relationship between PCs, PEs and SMs and cardiac damage mechanisms during development of DCM. The therapeutic effects of berberine on DCM are partly caused by interferences with PCs, PEs, and SMs metabolisms.

A power law distribution of metabolite abundance levels in mice regardless of the time and spatial scale of analysis

Biomolecule abundance levels change with the environment and enable a living system to adapt to the new conditions. Although, the living system maintains at least some characteristics, e.g. homeostasis. One of the characteristics maintained by a living system is a power law distribution of biomolecule abundance levels. Previous studies have pointed to a universal characteristic of biochemical reaction networks, with data obtained from lysates of multiple cells. As a result, the spatial scale of the data related to the power law distribution of biomolecule abundance levels is not clear. In this study, we researched the scaling law of metabolites in mouse tissue with a spatial scale of quantification that was changed stepwise between a whole-tissue section and a single-point analysis (25 μm). As a result, metabolites in mouse tissues were found to follow the power law distribution independently of the spatial scale of analysis. Additionally, we tested the temporal changes by comparing data from younger and older mice. Both followed similar power law distributions, indicating that metabolite composition is not diversified by aging to disrupt the power law distribution. The power law distribution of metabolite abundance is thus a robust characteristic of a living system regardless of time and space.

Retracted Article: High performance liquid chromatography coupled with high resolution mass spectrometry-based characterization of lipidomic responses from rats with kidney injuries

Metabolism of lipids is essential for the regulation of a variety of key cellular functions. Recent advances in high performance liquid chromatography coupled with high resolution mass spectrometry have expanded our knowledge of lipid metabolism in diseases. Currently, sepsis is one of the most important public health problems all over the world, which is a serious systemic inflammatory syndrome leading to infection by various agents or trauma and subsequently to a multiple organ dysfunction response. However, little is known about the lipids affected by sepsis and their roles in kidney injuries. In this study, we present targeted and non-targeted lipidomics strategies to discover the lipid metabolism variation in serum in rats with sepsis-induced kidney injuries. Liquid chromatography (LC) coupled with mass spectrometry (MS) and multivariate data analysis were used to obtain the global lipid metabolic profiles. In addition, biochemical parameters and histopathological examination results for the kidney were analyzed to support the pathological changes during sepsis-induced kidney injury. The identification of ten proposed lipids and five relevant pathways will promote a better understanding of lipid profile alterations in kidney injury. The results suggested that lipid metabolism in sepsis-induced kidney injury had changed significantly and contribute by offering potential targets for clinical diagnosis and therapy in the future, which would be worth further studies to broaden the applications of high performance liquid chromatography coupled with high resolution mass spectrometry in the study of lipid metabolism.

In this study, we present targeted and non-targeted lipidomics strategies to discover the lipid metabolism variation in serum in rats with sepsis-induced kidney injuries.